Patient Video - Alicia’s story: How did genetic and biomarker testing impact your options for ovarian cancer clinical trials?
Alicia describes how genetic and biomarker testing has significantly impacted the treatment of her ovarian cancer because the results have opened doors for clinical trial participation. She qualified for a clinical trial focused on BRCA-negative, HRD-positive patients. Alicia shares that her ongoing experience in the trial has been great and that she has a lot of confidence in it, as her cancer has not recurred in 4 years.
This educational activity has been developed by the National Ovarian Cancer Coalition in collaboration with Mechanisms in Medicine Inc.
This activity is supported by educational grants from: Alkermes plc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Inc., Eisai Inc., Foundation Medicine, Inc., Genentech, a Member of the Roche Group, GSK, ImmunoGen, Inc., Merck & Co, Inc., Novartis, Novocure Inc., Pfizer, Inc.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.